Veeva Rose 8% Today. Here’s Where the Stock Could Head in 2026

Key Stats for Veeva Stock

• Today’s Performance: 8%
• 52-Week Range: $148 to $311
• Valuation Model Target Price: Around $243
• Implied Upside: About 42%

Analyze your favorite stocks like Veeva Systems with TIKR (It’s free) >>>

What Happened?

Veeva Systems Inc. stock rose about 8% today, trading near $171 per share as investors looked past recent software valuation pressure and focused on a clearer AI product story, strong quarterly execution, and analyst target updates.

Veeva stock moved higher because the company gave investors a more concrete reason to believe its AI strategy can become a real business driver. Veeva acquired Copli and launched Veeva Falcon MLR, an agentic medical, legal, and regulatory review product for life sciences companies that uses AI agents to help review drug marketing and medical content for compliance, and Veeva says it could eliminate 70% or more of manual MLR labor within five years.

The recent earnings call also supported the rebound, as CEO Peter Gassner said Falcon is “our first step into digital labor,” giving investors a clearer view of how Veeva wants to use AI beyond basic software features. Veeva also reported Q1 revenue of $883 million and non-GAAP operating income of $395 million, while management highlighted Vault CRM momentum, with more than 150 customers live, over 40 migrations completed, and a win rate above 80% this year.

The Salesforce comparison matters because CRM migration remains one of Veeva’s clearest competitive stories. Management said Veeva has won 10 of the tracked top 20 CRM decisions versus 6 for Salesforce, with 4 decisions still remaining. Salesforce is much larger, with Q1 revenue of about $11 billion and a non-GAAP operating margin near 35%, while Veeva’s latest quarter showed revenue of about $883 million and a non-GAAP operating margin near 45%, highlighting Veeva’s smaller scale but stronger profitability in its focused life sciences niche.

Value Veeva Systems instantly (Free with TIKR) >>>

Is Veeva Undervalued?

Under valuation assumptions, the stock is modeled using:

• Revenue Growth (CAGR): Around 13%
• Operating Margins: Around 45%
• Exit P/E Multiple: Around 19x

Revenue growth is expected to settle into the low-double-digit range as Veeva continues expanding across clinical, regulatory, data, and commercial software for life sciences customers.

The model’s roughly 13% revenue growth assumption depends on Veeva capturing more spending across Vault, Data Cloud, Crossix, Vault CRM, and AI-enabled products like Falcon MLR.

The roughly 45% operating margin assumption is high but defensible because Veeva’s subscription software model can scale efficiently if customers adopt more products without requiring a large increase in service costs.

The roughly 19x exit P/E multiple is conservative for a high-quality vertical software company, which helps keep the valuation model from relying on an aggressive multiple.

See analysts’ growth forecasts and price targets for Veeva Systems (It’s free) >>>

Based on these inputs, the model estimates a target price of around $243, implying about 42% total upside over roughly three years, indicating the stock appears undervalued at current prices.

Results over the next year will likely depend on how quickly Veeva turns its AI roadmap into real customer adoption and revenue expansion. Falcon MLR could become a meaningful growth driver if large pharma companies use it to cut review times and reduce manual compliance work. The ongoing shift to Veeva Vault CRM also gives the company a chance to strengthen customer relationships as life sciences firms move away from Salesforce and other legacy commercial systems.

Data Cloud adoption adds another layer of upside if customers spend more on connected clinical, commercial, and patient data products.

At current levels, Veeva looks undervalued, with future performance driven by AI product execution, platform expansion, CRM share gains, and margin durability rather than a simple rebound in software spending.

How Much Upside Does VEEV Stock Have From Here?

Investors can estimate Veeva Systems’ potential share price, or what any stock could be worth, in under a minute using TIKR’s New Valuation Model tool.

All it takes is three simple inputs:

1. Revenue Growth
2. Operating Margins
3. Exit P/E Multiple

From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.

If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.

Value Veeva Systems in under 60 seconds with TIKR (It’s free) >>>